Answers are grounded in this paper and cite their sources.
Systematic review reveals GLP-1 receptor agonists enhance cognitive function in AD patients with T2DM, suggesting potential benefits in treatment.
GLP-1 RAs positively affect cognitive function in AD patients with T2DM. However, their efficacy on disparate cognitive domains requires further replication in larger scale controlled clinical trials.
No takes yet. Share an insight, caveat, or question.
Ballum et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: